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                               INTRODUCTION   
                 Radiotherapy is a important modality in management of patients with  
cervical cancer.Discovery of Xrays by Wilhelm Conrad Roentgen on December  
28,1895,marked the dawn of radiation oncology. In 1902 Xrays were used to  
treat cervical cancer,which was the first documented evidence.In early years  
they had limited knowledge about the radiobiology and dose distribution in the  
tumour and surrounding normal tissue.Hence the dose was entirely empirical so  
complications and failures are common  
           To achieve cure of a patient with any cancer ,radiotherapy,must eradicate  
every stem cell associated with the tumour and also those that are generated  
during course of treatment.The larger the course of treatment  more the stem  
cells can repopulate,increasing the number of stem cells that have to be  
killed.As overall treatment time increases the probability of local tumour  
control decreases.In cervical cancer Overall treatment time includes combined  
external beam radiation with or without chemotherapy and  
brachytherapy.Studies have shown that overall treatment time in carcinoma  
cervix should be as short as possible and should not exceed 56 days  
           Both surgery and radiotherapy can be offered as primary treatment in  
stage I-IIA disease as both treatment options showed  similar cure rates in this  
population .Standard treatment for patients with more advanced disease is  
concurrent chemoradiation and external beam RT followed by brachytherapy    
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                      CERVICAL CANCER EPIDEMIOLOGY 
                Cervical cancer is the 4th most common cancer among females all  
over  the world and is one of the most common causes of  cancer related 
mortality globally.World wide there were 5,27,600 new cases with 
265,700 deaths in 2012.The incidence in age group 15-39 years old is16 per 
1,00,000 women .In India which is the second most populated country cervical 
cancer is the second  most common cancer in females with annual incidence of 
1,22,844 cases.Globally cervical cancer incidence varies with variation  in 
cultural outlook towards sexual practices and differences in the mass 
screening programs.The incidence of cervical carcinoma is more in populations  
with poor rates of screenings and high HPV infection. 
               The first screening test used for cervical cancer is the pap smear test 
which   was developed by George papanicolaou,a  greek cytopathologist 
in1923. He incidentally found cancer cells in cervical smears of patients in 
whom in was observing various cellular changes during menstruration. 
              The high incidence of advanced  cervical cancer in developing 
countries  due to lack of screening  which  help in detection of  precancerous 
and early lesion. Effective methods of screening that can be used in countries 
that are still developing and under developed includes visual inspection with  
Using acetic acid or lugols iodine and testing for HPV DNA in cervical cell 
samples.HPV Types(16 and 18)cause 70% of cervical cancers and precancerous 
lesions in the cervix. Fact is cervical cancer is most common HPV related 
malignancy with almost all cases of cervical cancer linked to HPV 
infection.Varies risk factors of Various trials have been performed in low 
economy countries  like India to find the effectiveness of HPV testing and in 
one such trial  it was found that there a 50%  reduction in risk of  developing 
advanced cervical  cancer due to HPV testing. 
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           The first HPV vaccine-Gardisil quadrivalent HPV recombinant vaccine 
was approved and came to use in the month of june in 2006 .The following year 
2007 the bivalent HPV vaccine cervarix was approved by the FDA.The vaccine 
showed 100% efficacy in vaccinated women and vaccine must be administered  
before sexual exposure. 
             HPV Vaccine is recommended for all boys and girls ages 9-16 years 
,two doses 6 months apart.   
             TYPES -    Cervarix- Only females – 16,18 
             Gardasil- Males and females – 6,11,16,18 
Nanovalent - Males and females – 6,11,16,18,31,33,45,52,58 
 DOSE –0,1,6 months 
            Herpes simplex virus 2 has been implicated as a cofactor for 
development of cancer cervix.Many studies have implicated that herpes simplex 
virus 2 showes higher incidence in cervical cancer patient but no definitive 
evidence was proved. 
            Association between HIV and cervical cancer is proven ,since AIDS will 
cause immunosuppression. 
             Recently smoking and tobacco on causation of cervical cancer has been 
seen in new light.Women who smoke keep cervical HPV infection longer and  
so have more chance of developing cervical cancer than non smokers. In Indian 
scenario passive smoking is usally more common than active smoking. 
            Diethylstilbestrol which was used in 1940 s for prevention of recurrent 
and   threatened miscarriages was found to be associated with the development 
of clear cell carcinoma of cervix and vagina.So it was banned by FDA in the 
year 1971. 
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          In India screening programs are available only at tertiary care centre and  
women are not motivated enough for screening.Usually women who are 
symptomatic only end up in screening program resulting in detection only at 
advanced stages of disease. 
               
Guidelines for screening 
i)Women under 21 years should not be screened 
ii)Women aged 21 to 29 years-Pap smear test every 3 years 
iii)Women starting 30 years –preferred screening is Pap smear test with HPV  
test every 5 years until age 65 or Pap smear only ever 3 years until 65 years 
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                                 ANATOMY OF CERVIX 
The uterus is a pear  organ situated in the true pelvis above the vagina but 
posterior to the bladder and anterior to the rectum. The uterus is made up of the 
corpus superiorly and cervix inferiorly. The uterus  measures  7x8cm in lengh 
,5-6cm wide and 2-3cm thick.Cervix measures 3x3cm and is divided into a 
superior supravaginal portion above the ring containing the endocervical canal 
and the vaginal portion protruding into the vaginal vault. Central in the rounded 
vaginal region is the external os bounded by the anterior and posterior lips of 
the cervix, extending inward to the internal os ,the endocervical canal and 
endometrial canal 
 
 
     Lymphatic drainage  is through the external iliac  (of which the 
obturator nodes are the innermost) and the hypogastric nodes. The pelvic 
lymphatics drain into the common iliac and the paraaortic lymphnodes 
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                             Lymphatic drainage of cervix 
      
 
    PERCENTAGE OF LYMPH NODAL METASTASIS CA CERVIX 
STA        
PELVIC NODAL 
METASTASIS% 
PARA AORTIC 
NODAL METASTASIS 
% 
IA1 1 <1 
IA2 2 <=5 
IB 10 10 
IIA 15 15 
IIB 20 15 
IIIA 25-30 20  
IIIB 40-50 30-35 
IV 50-60 40-45 
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ETIOLOGY OF CANCER CERVIX 
 Socioeconomic status 
 Access to health care 
 Parity 
 Smoking 
 Presence of other infections 
 Immune status 
 Nutritional status 
     HPV 
Studies suggest than more than 90 percentage of cervcal cancer is related 
to HPV infection.HPV is a sexual transmitted infection. HPV is small double 
stranded DNA. 
 Types - 16,18,31,33,35,39,45,51,52,56,58 
     HPV genome causes alteration in the chromosomes of the cells in the 
host by integrating with the host cell chromosomes. It encodes for E5,E6,E7 
proteins which alter cellular proliferation. E6 inactivates p53 which results in 
chromosomal instability which inhibits apoptosis and activates telomerase. 
Incidence is between 25 – 35 years.It can take as long as 10-20 years after initial 
exposure for cancer to occur 
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 Other  factors associated with carcinoma cervix- 
 Early age at first sexual intercourse. 
 History of multiple sexual partners. 
 A male partner with a history of multiple partners. 
 Large number of pregnancies. 
 History of sexually transmitted diseases/HIV 
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                 NATURAL HISTORY OF CARCINOMA CERVIX 
Squamous cell carcinoma of  uterine cervix usually originates at the 
squamocolumnar junction (transformational zone) of the endocervical canal and 
the exocervix. There is a structural progression from normal to higher levels of 
dysplasia.60% of CIN I and 40 % of CIN II will regress. Higher levels of 
dysplasia are more likely to transform into cancer. More so in the presence of 
cofactors like smoking ,impaired immunity. The transformation may be slow 
(10 – 20 years) or a rapid development in an aggressive disease. 
Malignancy occurs when cells break the basement membrane and invades 
into the stroma of the cervix. This might result in spread to pelvic lymph nodes 
or distant organs. 
Early detection at this point by a Pap smear will result in using minimally 
invasive therapy. However if the tumour progresses, it will become a superficial 
ulceration or exophytic tumour in the ectocervix or endocervix. If the cancer is 
not treated at this point it will spread further to the adjacent vaginal fornices, 
paracervical or parametrial or surrounding organs like urinary bladder or rectum 
or both. Paracervical extension is related to the depth of stromal invasion, 
tumour size, lymphatic invasion and the presence of lymph node metastasis.10 – 
30 %  of patients with carcinoma of the uterine  cervix have extension to the 
lower uterine segment and the endometrial cavity. Regional lymphatic or 
hematogenous spread may occur and increases with stage although it does not 
occur in a definite order. Spread can progress to the obturator lymph nodes  
 
[Type text] 
 
15 
 
(medial group of external iliac chain),other external iliac nodes to the 
hypogastric nodes, common iliac or paraaortic lymph nodes. The incidence of 
metastasis to pelvic or paraaortic lymph nodes depends on the stage of the 
disease. Spread through the venous plexus and paracervical veins resulting in 
hematogenous dissemination though rare in early stages is quite common in 
advanced stages. Spinal epidural compression from metastatic tumour often 
involving lumbar segments can occur rarely and spread to brain, lung and heart 
has also been reported. 
 
 
 
 
             
 
 
 
 
Site of metastasis Incidence% 
Lung 21 
Bone 10 
SCL Node 7 
Liver 4 
Peritoneal/abdomen 4 
Inguinal Lymph nodes 3 
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                                     PATHOLOGY 
Squamous cell carcinoma – 90% - Squamous-cell carcinomas are divided 
intothree types: large-cell keratinizing and nonkeratinizing and small-cell 
type, and they are subdivided according to the degree of differentiation 
into well, moderately, or poorly differentiated 
 Adenocarcinoma -7 – 10 % 
 Clear cell mesonephric type – 1- 2 %.  
PROGNOSTIC FACTORS 
I) PATIENT FACTORS 
1. Age 
2. Race 
3. Socioeconomic status 
4. General medical factors like anemia and hypoxia 
II) TUMOR FACTORS 
1. HPV subtypes 
2. Tumor volume 
3. Grade of the tumor 
4. Treatment duration 
5. Biomarkers like VEGF,BAX,BcL2   
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                  FIGO STAGING-CARCINOMA CERVIX 
              The FIGO staging system is based on clinical evaluation (inspection, 
palpation, colposcopy); roentgenographic examination of the chest, kidneys, 
and skeleton and endocervical curettage and biopsies. Lymphangiograms, 
arteriograms, imaging findings, and laparoscopy or laparotomy findings should 
not be used for clinical staging. Suspected invasion of the bladder or rectum 
should be confirmed by biopsy. Bullous edema of the bladder and swelling of 
the mucosa of the rectum are not accepted as definitive criteria for staging 
I-Carcinoma confined to the uterus-extension in corpus should be disregarde 
IA-Preclinical invasive carcinoma diagnosed only by microscopy. 
Stromal invasion with a maximum depth of 5.0mm measured from the base of 
the epithelium and a horizontal spread of 7.0mm or less. Vascular space 
involvement, venous or lymphatic does not affect classification. 
IA1 –Measured stromal invasion 3.0 mm or less in depth and 7.0 mm or 
less in horizontal spread. 
          IA2 – Measured stromal invasion more than 3.0 mm  and non 5.0mm 
with  7.0 mm or less in horizontal spread. 
IB – Clinically visible lesion confined to the cervix or microscopic lesion 
greater than IA2. 
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         I B1 – Clinically visible lesion 4.0 cm or less in greatest dimension 
I B2 – Clinically visible lesion more than 4.0 cm in greatest dimension. 
II –Cervical carcinoma invades beyond uterus but not to pelvic wall or to 
lower third of vagina. 
II A – Tumour without parametrial invasion 
II A 1 – Clinically visible lesion 4.0 cm or less in greatest dimension  
II A 2 -  Clinically visible lesion more than 4.0 cm in greatest dimension. 
II B – Tumour with parametrial invasion 
III – Tumour extends to pelvic wall and / involves lower third of vagina, 
and / or causes hydronephrosis or non functioning kidney. 
III A-Tumour involves lower third of vagina ,no extension to pelvic wall. 
III B – Tumour extends to pelvic wall and /or causes hydronephrosis or 
nonfunctioning kidney. 
IV A – Tumour invades mucosa of bladder or rectum,and/or extends 
beyond true pelvis (bullous  edema is not sufficient to classify as IV A) 
IV B – Distant metastasis including peritoneal spread, involvement of 
supraclavicular mediastinal or paraaortic lymphnodes, lung, liver or bone  
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                                   DEMOGRAPHIC DATA       
MMTR DATA 
Cervix 
cancer  
1982-
1986  
1987-
1991  
1992-
1996  
1997-
2001  
2002-
2006  
2007-
2011  
2012-
2013  
Annual No. 
of cases:     
Women  
563  535  465  516  445  400  193 
% to total 
cancers  
37.7  31.5  26.1  24.6  18.5  14.3  12.8 
Women: 
CIR / 
100,000  
33.7  29.6  24.0  24.8  20.4  17.5  16.5 
ASR / 
100,000  
44.5  37.8  29.3  29.0  22.1  17.8  15.7 
Cumulative 
Risk % - 
One in  
21  25  31  31  39  47  53 
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               TREATMENT MODALITIES FOR CERVICAL CANCER 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
                 
DIAGNOSIS OF     
CARCINOMA CERVIX 
         STAGE IA –IB1            STAGE IB2-IIA           STAGE IIB-IVA 
CLINICAL AND 
RADIOLOGICAL STAGING 
RADICAL HYSTERECTOMY 
WITH PELVIC NODAL 
DISSECTION 
RADICAL RT WITH 
WEEKLY CISPLATIN 
RADICAL 
HYSTERECTOMY 
WITH NODAL DISSEC 
RADICAL RT WITH 
WEEKLY CISPLATIN 
RADICAL RADIATION 
NEGATIVE NODES POSITIVE NODES 
LOW RISK-NO 
ADJUVANT 
TREATMENT 
INTERMEDIATE RISK-
RT  ONLY 
HIGH RISK-
CHEMORADIATION 
CHEMORADIATION 
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Premalignant squamous lesions of the cervix were earlier named with 
terms like mild,moderate,severe.Rubin in the year 1910 first introduced the term 
carcinoma in situ for invasive carcinoma.In the year  1967 Richard introduced 
the concept CIN with varying degree of atypia. 
 
 
WHO in 1975 classified CIN into three categories 
CIN1,CIN2,CIN3.CIN1 is mild dysplasia confined to the basal 1/3 of the 
epithelium.CIN2 is moderate dysplasia confined to the basal 2/3 of the 
epithelium.CIN3 is severe dysplasia involves more than 2/3 of epithelium. 
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GENERAL PRESENTATION: 
           Low back pain and pain in gluteal region may be present due to advanced 
aggressive disease or due to enlarged pelvoc adenopathy which causes pressure 
effect on the lumbosacral nerves or hypogastric nerves . 
              Patients can also present with bleeding per vaginum to massive tumour 
bleeding which can be life threatening.Prongled history of minimal bleeding 
may be associated with anaemia and generalised tiredness. 
                      Locally aggressive disease an cause invasion of organs surronding  
 
Hematuria  and dysuria can occur because of invasion of the bladder and blood  
 
in stools or frank blood in rectum and rectal pain can occur due to rectal  
 
involvement or  hydronephrosis and uremia secondary to ureteral obstruction by  
 
tumor may occur.  
 
                          In very advanced and neglected cases, fistula formation may  be  
 
present with fecal or urinary diversion into the vagina. Fever secondary to local  
 
infection of the cervix, vagina, and vulva, or urinary tract infections with the  
 
possibility of pyelonephritis may be seen.  
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MANAGEMENT OF CARCINOMA CERVIX AND OVERVIEW 
    
 
 Carcinoma In Situ  :Patients with carcinoma in situ, which may include  
 
severe dysplasia, usually are treated with a total abdominal hysterectomy, with  
 
or without a small vaginal cuff. The decision to remove the ovaries depends on  
 
patient age and the status of the ovaries.  Intracavitary irradiation (tandem and  
 
ovoids) may be useful for the treatment of in situ carcinoma, particularly in  
 
patients with strong medical contraindications for surgery or when there is  
 
multifocal carcinoma in situ in both the cervix and vagina   
 
FIGO Stage IA:  
 
Early invasive carcinoma of the cervix (stage IA2) usually is treated with a total  
 
abdominal or modified radical hysterectomy, but it can be treated with  
 
intracavitary radioactive sources alone.  
 
FIGO Stages IB and IIA:  
 
The choice of definitive chemoradiation or radical surgery for stage IB and IIA  
 
carcinoma of the cervix remains highly controversial, and the preference of one  
 
procedure over the other depends on the general condition of the patient and the  
 
characteristics of the lesion. Tumor control and survival are equivalent with  
 
either modality.  
 
FIGO Stages IIB, III, and IVA:  
 
Patients with stage IIB and III tumors are treated with chemoradiation alone.  
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Patients with stage IVA disease (bladder or rectal invasion) can be treated either  
 
with pelvic exenteration, or with high doses of external irradiation to the whole  
 
pelvis, intracavitary insertions, and additional parametrial irradiation.  
 
                     Concomitant use of irradiation and cisplatin, has been administered  
 
to obtain a radiosensitizing effect. Several randomized trials have shown  
 
improved outcome with concomitant irradiation and chemotherapy compared  
 
with irradiation alone.   
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Adjuvant postoperative therapy: 
 
The decision on adjuvant therapy following hysterectomy depends 
on the prognostic factors like status of the lymph nodes, size of the primary 
tumor, depth of stromal invasion, presence or absence of lymph-vascular space 
invasion, presence or absence of parametrial extension, histologic cell type and 
status of the vaginal margins. There were three independent prognostic factors: 
 
 The clinical size of the tumor. 
 
 The presence or absence of lymph-vascular space invasion. 
 
 The depth of tumor invasion. 
 
 
The risk stratification is done by calculating the GOG score. 
The GOG score is calculated by multiplying the relative-risk for depth X 
tumour size X lympho vascular space involvement. 
 
 Low risk (GOG score less than 40) – No adjuvant therapy. 
 
 Intermediate risk (GOG score 40-120) – only radiation. 
 
 High risk (GOG score more than 120) – concurrent 
chemoradiation. 
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 CONCURRENT CHEMORADIATION IN CARCINOMA CERVIX 
          Use chemotherapy along with radiation, has been proven to 
increase either mutual or simultaneous sensitization. Like more than 100 
years ago there is a example  when radiation treatment and systemic 
benzene treatment were combined for the treatment of leukemia. In the 
late 1970 s Steel and Peckham developed a conceptual framework for 
analyzing drug-radiation interactions . In this seminal work, four 
mechanisms were described in which combined modality therapy could  
improve therapeutic outcome they are spatial cooperation.toxicity 
independence,protection of normal tissue.and enhancement of tumour 
response 
       Now for more than 20 years , these mechanisms provided the 
backbone for evaluating chemoradiation combinations clinically. Based 
on these clinical investigations, combined  with the rapid emergence of 
molecularly targeted agents, Bentzen and colleagues proposed an 
updated conceptual framework to evaluate drug-radiation 
combination.One of the clearest clinical examples demonstrating 
improved outcomes of combined chemoradiation is in locally advanced 
cervical cancer. 
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  In earlier days radiation therapy was the  most effective modality for treatment 
of carcinoma cervix,  when either surgical resection is not  possible or when 
surgical resection is not medically feasible. Many cases fail in the scenario of 
bulky local disease or regional metastatic disease. For the past 45 years many 
studoies and trials  have been conducted to explore the pontential agents which 
are likely to increase the possible cure in these patients. Initial studies evaluated 
the potentcy of hydroxyurea to increase the cure with radiation. Many studies 
found to have benefit, but a Cochrane review in 2004 proved that there is no 
evidence to support the use of hydroxyurea combined with radiation in the 
treatment of carcinoma cervix. Another cause for selective radio resistance, in 
large tumours was tissue hypoxia. Many studies combined radiation with 
hypoxic- cell radiosensitizers like misonidazole, pimonidazole, but none proved 
the benefit of these agents in carcinoma cervix. Observation from all these 
earlier trials were taken together,and in 1996 the National Institutes of Health 
Consensus Statement on Cervical Cancer stated that there was no proven benefit 
on combining chemotherapy with radiation in locally advanced cervical cancer. 
    For the next  4 years (1996 to 1999)a series of five phase three randomised 
clinical trials  combining radiation with cisplatin revolutionized treatment of 
carcinoma cervix. Based on the results of these trials, in the 2nd month of 1999, 
the National Cancer Institute(NCI) issued a clinical announcement stating  
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that strong consideration should be given in the incorporation of concurrent 
cisplatin-based chemotherapy with radiation therapy in women who require 
radiation therapy for treatment of cervical cancer. 
VARIOUS TRIALS FOR CONCURRENT CHEMORADIATION 
GOG 85 & SWOG 8695 Study- Charles W.Whitney et al: 
 
Patients with stage IIB- IVA(368) were randomised based on 
eligibility to receive either hydroxyurea or cisplatin /5 flurouracil. The median 
follow up for 8.7 years.There was a significant changes in 5-year progression 
free survival with cisplatin/5-Flurouracil (57% versus 47%) and overall survival 
at 5 years(62% versus 50%). Thus proving that cisplatin based regimen is 
superior compared to hydroxyurea 
 GOG 120 study- Peter.G. Rose et al: 
 
Patient with stage IIB–IVA were randomised either to weekly 
cisplatin alone or hydroxyurea alone or combination with cisplatin, 5-flurouracil 
and hydroxyurea. This study concluded that there is a significant survival 
benefit with cisplatin containing regimens.3 year overall survival was 65% for 
platinum based arms versus 47% in non platinum based arm. This study also 
concluded that weekly cisplatin is effective and less toxic.  
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RTOG 90-01 protocol- Mitchell Morris et al: 
Patients with stage IB–IVA were randomised to either pelviradiation with 
cisplatin and 5-flurouracil versus pelvic with para aortic radiation. There was a 
significant difference in the 8 years disease free survival (61% with 
chemotherapy versus 46%) and  overall survival (67% with chemotherapy 
versus 41%). Interestingly there was no change inthe para aortic failure rates 
GOG 123 study- Henry M.Keys et al: 
     Women with bulky stage IB cervical cancers were randomly assigned to 
receive radiotherapy alone or in combination with cisplatin, followed in all 
patients by adjuvant hysterectomy. There was a significant change in 3-year 
progression free survival(79% with cisplatin versus 67%); 3- year overall 
survival(83% with cisplatin versus 74%). The pathogical complete response 
rates were also higher with cisplatin. This study concluded that weekly cisplatin 
is superior to radiation alone in bulky stage IB2 
Intergroup 0107 (SWOG 8797/GOG 109/RTOG 91-12)- Pearcey et al: 
Patients eligible for this intergroup study were those with stage IA2, IB, or IIA 
carcinoma of the cervix who was initially treated with radical hysterectomy and 
pelvic lymphadenectomy and who was found to have positive pelvic lymph 
nodes, positive margins, and/or positive parametrial infiltration on microscopic 
evaluation. They were randomised to either concurrent chemoradiation with  
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cisplatin and 5-fluro uracil or radiation alone. There was a significant difference 
in 4 year over all survival (81% with concurrent chemoradiation versus 71%). 
Overview of concurrent chemoradiation trials: 
                 The five studies had different eligibility criteria, but in total included 
a broad spectrum of clinical presentations: 
 
 locally advanced tumors for which chemoradiation represented primary 
therapy,

 bulky early-stage cancers in which chemoradiation was delivered prior to 
adjuvant hysterectomy, and

 postradical hysterectomy cases with high-risk pathologic factors for 
whom adjuvant chemoradiation was given.
 
There was a consistent statistically significant survival advantage 
favoring the RT arm that included a concurrent cisplatin-based regimen, as 
compared with RT alone or RT combined with hydroxyurea, with a dramatic 
30% to 50% decrease in the risk of death from cervical cancer. Several of these 
studies, have been updated and confirm that the statistically significant survival 
advantage of cisplatin based chemoradiation is maintained over the long term, 
and they validate the 1999 NCI clinical alert. 
 
 
 
[Type text] 
 
31 
 
In 2010, Cochrane gynaecological oncology group evaluated all 
concurrent chemoradiation trials. It is a review of twenty four trials (21 
published, 3 unpublished) and 4921 patients and concluded, ‖Concomitant 
chemoradiation appears to improve overall survival and progression-free 
survival in locally advanced cervical cancer. It also appears to reduce local and 
distant recurrence suggesting concomitant chemotherapy may afford 
radiosensitisation and systemic cytotoxic effects. Some acute toxicity is 
increased, but the long-term side effects are still not clear. 
The other chemotherapeutic agents which have been tried along 
with irradiation to the pelvis are carboplatin, 5-Fluoro uracil, epirubicin, 
gemcitabine and mitomycin C, either alone or in combinations. Balanced 
against the indeterminate individual trial results described above, a recent 
comprehensive meta-analysis has suggested that nonplatinum agents may also 
improve outcome when combined with RT and deserve further evaluation. 
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        ACUTE TOXICITIES IN CONCURRENT CHEMORADIATION 
 
Concurrent chemoradiation with cisplatin based chemotherapy, 
marked its success through a series of trials in improving not only the local 
control rate, but also the overall survival. In the late 1970s Soloway and 
colleagues demonstrated radiosensitization in a murine model of transitional 
cell carcinoma. In a study of 19 human cervical-cancer cell lines, Britten et al. 
found that radiotherapy and concomitant treatment with cisplatin increased the 
rates of death of these tumor cells. However, radiosensitivity was increased in 
only four cell lines, suggesting that the effect of this combined therapy is 
primarily caused by direct cytotoxicity.Cisplatin is Cis-
diamminedichloroplatinum, a water soluble coplanar complex, which is 
converted to its active form by replacement of its chloride ions with hydroxyl 
groups[30]. The cytotoxicity of cisplatin is primarily ascribed to its interaction 
with nucleophilic N7-sites of purine bases in DNA to form both DNA–protein 
and DNA–DNA interstrand and intrastrand crosslinks[32]. The basis for 
interaction between cisplatin and radiation may be appreciated at multiple 
levels,like by increased formation of toxic platinum intermediates in the 
presence of radiation-induced free radicals,or the capacity of cisplatin to 
scavenge free electrons formed by the interaction between radiation and DNA 
that may fixate otherwise reparable damage to DNA, 
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 a radiation-induced increase in cellular cisplatin uptake,

 a synergistic effect because of cell cycle disruption, and

 the inhibition of repair of radiation-induced DNA lesions.
 
The toxicity of concurrent chemoradiation in carcinoma cervix can be attributed 
to  
          Cytotoxic effects of chemotherapy. 
          Toxicity due to pelvic radiation. 
            Enhanced toxicity due to synergistic   
 
Cytotoxic effects of chemotherapy: 
Edward  Chu  in  his  ―Cancer  Chemotherapy  Drug  Manual‖  describes  13 
toxicities due to cisplatin. The notable ones are nephrotoxicity, nausea & 
vomiting, myelosupression, neurotoxicity and ototoxicity. The other likely side 
effects are hypersensitivity, optic neuritis, papilloedema, cerebral blindness, 
transient elevation of liver function tests, metallic taste of food & loss of 
appetite, vascular events like myocardial infarction, cerebral infarction, 
Raynaud’s phenomena, azoospermia, alopecia and syndrome of inappropriate 
secretion of anti diuretic hormone. Toxicity due to pelvic radiation: 
          Acute symptoms of the rectum can be seen early in the course of radiation 
therapy for cancers in the pelvic region. Symptoms usually begin following 20 
Gy of standard fractionation. Early symptoms may include tenesmus, bleeding,  
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and diarrhea. O’Brien et al. found that the presence of acute proctitis was the  
only factor to predict any of the late rectal symptoms of urgency, frequency, and 
diarrhea. Similarly Acute sequelae during radiation commonly include 
frequency and dysuria. These symptoms typically occur following more than 20 
Gy to the bladder with conventional fractionation. 
 
Regarding treatment related lymphoedema there is a report of 
patients treated with surgery and radiation for cervical cancer. 41% had 
unilateral lymphoedema. Of these patients, 28% had a slight swelling, 6% had 
moderate swelling and 7% had severe swelling, which was interpreted as 
treatment-induced lymphedema. 22% of the patients had lymphoedema that was 
severe enough to cause symptoms. 
 
Insufficiency fractures in the pelvic bones and femoral neck 
fractures do occur do to the effect of radiation on bone. The bone marrow is one 
of the most radiosensitive organs in the pelvis. Approximately 40% of the total 
body bone marrow reserve lies within pelvic bone. Hematologic toxicity can be 
seen acutely during radiation and exposure to radiation can result in long-term 
myelotoxicity. The radiation dose, dose rate, and volume all affect the acute 
response of the bone marrow to therapy. When small bone marrow volumes are 
irradiated, bone marrow in unexposed areas of the body responds by increasing 
its population of progenitor cells meeting the demands for haematopoiesis.  
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Therefore, acute effects are not seen unless a substantial portion of 
the marrow is exposed. With exposure to large bone marrow volumes, 
neutropenia occurs in 2–3 weeks followed by thrombocytopenia and then 
anemia in 2–3 months. 
Enhanced toxicity in concurrent chemoradiation: 
 Similar to the enhanced tumour killing effect by  combined chemoradiation,  
there is also increased incidence of toxicity in  these patient. In the GOG 123  
study by Keys et al, it is observed that the   incidence of grade 3&4 toxicity  
between the radiation only arm and  concurrent chemoradiation (with cisplatin)  
arm was comparable for genitourinary, cutaneous and neurological toxicity. But  
for haematological toxicity, the incidence was 21% in the chemoradiation arm  
versus 1.6% in the radiation arm. Similarly for gastrointestinal toxicity, the  
incidence was 14.2% in the chemoradiation arm versus 4.8% in the radiation  
arm. These data clearly proves that there is enhance myelotoxicity, when  
cisplatin is combined with radiation. The myelotoxicity is more profound when  
radiation is combined with other chemotherapeutic agents other than cisplatin. 
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      PATHOPHYSIOLOGY OF CONCURRENT CHEMORADIATION 
Chemotherapy given along with radiation has a great influence on cancer 
treatment.  The use of chemotherapy along with radiation  has been proven to be 
far better than radiation alone in many clinical trials though there associated 
toxicities 
Rationale behind concurrent chemoradiation 
 a)Causes reduction in the number of cells in tumors undergoing 
radiotherapy. This occurs by its separate cytotoxic action  and by making tumor 
cells more suseptable to be killed by the ionizing rays. 
 b)It also acts on metastatic disease .There must be a positive 
Therapeutic Index ( >1)  for concurrent chemoradiation to be useful 
therapeutically. 
 Steel and  Peckham – classification 
Spatial cooperation 
Independent toxicity 
Enhancement of tumor response 
Protection of normal tissues 
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How cisplatin acts along with radiation? 
 It inhibits DNA synthesis 
 Causes inhibition of DNA interstand cross link elongation during      
transcription 
 Inhibition of repair occurring during radiation – induced  DNA 
damage 
    Emerging strategies for implementation of chemo radiation therapy  
1. Increasing antitumour efficacy of chemotherapeutic drugs by the 
following methods : 
 a. Chemical modifications of the drug. 
b. Making chemotherapeutic drugs more toxic to the tumour and at 
the same time less toxic to normal tissues by conjugating it with 
water soluble polymeric drugs such as polyglutamic acid. 
  c. Radiation modification of vasculature thereby enabling drugs to 
accumulate specifically in tissues 
   d. Radioprotective and chemoprotective drugs –eg.Amifostine WR – 
2721 (prodrug) is converted to WR – 10665 (active metabolite).It 
protects cisplatin induced nephrologic, ototoxicity and 
neurotoxicity. By the following mechanism of action – Free radical 
scavenging, Donation of hydrogen atoms to facilitate direct 
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chemical repair of DNA damage and Transcriptional regulation of 
genes involved in apoptosis,cell cycle regulation and repair. 
2. Normal tissue protection. 
3. Strategies to improve  delivery of  radiation therapy. 
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RADIOBIOLOGY-ACCERATED REPOPULATION OF TUMOUR 
CELLS 
         When ever we are treating a tumour with any form of cyto toxic agent   
which includes radiation,cytotoxic agents ,that is chemotherapy  the surviving  
tumour cells (the clonogens) tend to divide faster than before .This phenomenon  
is called as accelerated repopulation. 
       This phenomenon is illustrated in transplanted rat tumour.Which shows  
initial shrinkage of the tumour followed by regrowth occurs after a single dose  
of 20Gy of photons.The individual tumour cells that are surviving after  
treatment were dividing with a cycle time of 12 hours.The important thing is  
that during the perid that the tumour is overtly shrinking and regressing ,the \ 
cells that are surviving are dividing and increasing in number more rapidly than  
before treatment. 
     There is evidence of similsr phenomenon in humar tumours also.Withers and  
his colleagues  surveyed  the  literature on radiotherapy and estimated the dose  
to achieve local control in 50% of  cases as a function of the overall duration of  
fractioned treatment.This analysis proved that clonogens repopulation in rapidly 
 growing human cancer accelerates at about 28 days after radiotherapy  
initiation in  fractioned regimen.A dose increment of about 0.6Gy per day is  
required to comensate for this repopulation.Such a dose increment is consistant  
with a 4 day clonogen doubling rate.compared with median of 60 days for  
unperturded growth.The conclusion is that radiotherapy for fast growing  
tumours  should be completed as soon after it has beganand also it may be better  
to delay inititation of treatment than to introduce delays during treatment  which   
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will adversely affect outcome.The overall treatment time if  is too long ,the  
effectiveness of later dose fractions is compromised because the surviving  
clonogens present in the tumour can be triggered into rapid repopulation. 
This data is referred for radiotherapy.It might be anticipated however that  
similar phenomenon would apply to chemotherapy  and to combination of  
chemotharpy with radiothaerapy.But there is no evidence for that. 
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Ideal treatment period and how often treatment gaps occur during 
radiotherapy 
                     Radiotherapy is a important modality in management of patients  
with cervical cancer.To achieve cure of a patient with any cancer  
,radiotherapy,must eradicate every stem cell associated with the tumour and also  
those that are generated during course of treatment.The larger the course of  
treatment  more the stem cells can repopulate,increasing the number of stem  
cells that have to be killed.As overall treatment time increases the probability of  
local tumour control decreases. 
                     
 
 
                 The impact of the prolongation of treatment time in cervical cancer  
radiation therapy has already been studied. The increase in overall treatment  
time will decrease the survival at the rate of 0.3-1.6% per day. This impact is  
more in stage III.B disease and also been demonstrated in patients who were  
treated with  HDR  brachytherapy. But still there are  grey zones because  
brachytherapy  is  the integral part of cervical cancer treatment. The effect of  
chemotherapy and the duration between external radiation and brachytherapy  
need to be assessed. 
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                 In cervical cancer  Overall  treatment  time includes combined 
 external beam radiation and brachytherapy.Studies have shown that  
overall treatment time in carcinoma cervix should be as short as possible and  
should not exceed 56 days 
                  The total radiation dose should be given within a specific time.In  
daily clinical practice treatment breaks  due to radiation reactions,patients  
unwilling or unspecified reasons results in prolongation of overall treatment  
time.In many studies which includes planned interruptions (Split  
course)schedules,and also retrospective analysis suggest :the role of overall  
treatment time on outcome.This suggests the deleterious effect of accelerated  
repopulation of tumour clonogens. 
                       Evidence suggest that treatment gaps in radical radiation results in  
prolongation of overall treatment time affect local control rates and survival in  
certain cancer types.This is for different modalities of radiotherapy like                 
a)Radical radiation therapy 
b)External beam radiotherapy followed by brachytherapy(Treatment time  
overall includes time taken for combined therapy) 
c)Radiotherapy combined with chemotherapy(Treatment time overall includes  
time taken for combined therapy) 
d)Post op radiation therapy 
                     Patients are categorised under three group to manage treatment  
gaps 
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Group 1-Rapidly growing tumours like squamous cell carcinoma where  
treatment is given with radical intent.Many studies has been done on this  
group.Treatment duration overall should not be prolonged even by two days  
more than the prescribed. 
Group 2-Slower growing tumours like adenocarcinoma where treatment is  
given with radical intent.Treatment break of five days also have not been   
significant.Treatment duration overall still should not be prolonged by more  
than five days 
Group 3-This group belongs to patients that are treated with palliative  
intent.Here overall treatment time has no effect on achieving desired  
palliation.Only gaps more than 7 days needs to compensated.  
                         It is so assumed that fast growing tumour will be more affected  
by treatment breaks but it is not always true.there are exceptions,example is  
glioblastomas there has been no evidence of effect of treatment breaks on  
outcome since repair mechanism in brain tissue is different.Similarly  certain  
slow growing tumours like carcinoma anus does not significant change in  
outcome if the treatment gap is less than 5 days.When it comes to cancer  
cervix,head and neck malignancies ,lung cancer ,oesophageal cancer  
,medulloblastoma and primitive neuroectodermal tumors are greatly affected by  
gaps in treatment. 
                  In palliative scenario for reducing pain and bleeding,preventing  
ulceration,managing cord compression and superior vena caval  
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obstruction,reducing tumour burden overall treatment time prolongation does  
not matter that much ,but still for good palliation prolongation must not be more  
than 7 days. 
Question is how frequently treatment gaps occur during radical radiation  
therapy? 
          This is a difficult question since it varies with different tumour types and  
location and also when given concurrently with chemotherapy.Since acute  
morbidity due to radiation is different for different tumour types and location  
and also chemo can add up to the acute morbidity individually. In a study  
conducted in 80s and 90s on head and malignancies more than 30 percent  
treatment breaks were reported.With present guidelines such interruptions can  
be corrected. 
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                       Impact of length and timing of  treatment gaps  
                      The length of gap which results in significant effect on tumour  
control locally as discussed varies with different tumour type and site and also  
on standard department treatment times and protocols.On analysing data from  
split course regimens, studies show that fourteen to sixteen day interruptions  
definitely affect treatment outcome.Also prolongation of treatment by a week 
can result in 3 to 16% loss of local tumour control. Uncompensated gap of 1 day  
in a patient with cervical cancer can lead to reduction of local control of tumour  
by 1-1.4%.For locally advanced carcinoma cervix total treatment duration  
combining both external beam radiotherapy and brachytherapy should not be  
more than 56 days. 
                     The timing of breaks that occur during long course radiation does  
not seem to be significant .Recently studies done suggests that gaps arising in  
short course of treatment and during initial 28 days in long course RT are  
different from those appearing in later part of long course radiation.Also  
correction of breaks arising in the later part of long course radiation is always  
difficult to corrected since it requires large fractions over short time and can  
may cause increase in late morbidity.Studies have also shown that break on  
Monday and Friday increases weekend gap by 33% so it is worser than break  
that occur in the middle of the week. 
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                           Factors to determine treatment breaks 
 
Treatment associated factors 
I.Radiation related 
a)Diarrhoea-Proctitis 
b)Reactions to radiation 
II.Chemo related factors 
a)Nausea and vomiting 
b)Neutropenia 
Department associated factors 
a)Machine failure/service 
Patient associated factors 
a)Did not report to treatment due to personal reasons 
b)Natural disasters interrupting treatment 
Intercurrent illness associated factors  
a)Fever 
b)Respiratory infection 
c)Other non cancer related infections 
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                            MANAGEMENT  OF  TREATMENT  GAPS 
Prioritising patients on treatment when treatment interruption is inevitable 
Group-1 Patients with rapidly growing tumour which have short volume  
doubling time, who are treated with curative intent,since overall treatment time  
should not be prolonged by more than 2 days they should be given first  
priority.Squamous cell carcinoma of cervix falls under this group 
Group-2 Patients with slowly growing tumour who are treated with curative  
intent.Overall treatment time prolongation of 5 days may not affect  
survival.Next priority must be given to this group 
Group-3 Patients treated with palliative intent must be given least priority 
 
                  There should be no treatment gap in delivery of any radiotherapy  
treatment.Unless it is absolutely essential treatment breaks should be  
avoided.Every patients treatment schedule needs auditing.In case of unforeseen  
situation such as machine failure occurs atleast group 1 patients must be shifted  
to other machines if possible 
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                       Prevention of potential treatment gaps 
Department associated factors 
Machine related- 
                  Machine breakdown can cause treatment breaks to many patients  
simultaneously.Radiation oncology centres should  formulate plan to transfer  
patients to other machines when ever possible or fix the problem as early as  
possible so that patient can be treated  the same day.When a longer prolongation  
of machine failure is anticipated all measures must be taken to transfer patient  
to other machine or other centres,which is a complex issue since it requires  
temporary transfer of staff,doctors and physicist.Also in such cases replanning  
might be required if the other linear accelerator is not compatable.In case of  
machine service ,all patients should be transferred to alternate matched linac or  
service day must be a week end.                                          
                  Brachytherapy list for every week   should have a extra slot for  
emergency.                                                      
Public holidays- 
                     Treating patients on a public holiday is very difficult. At least  
group1 patients must be treated.Centres should have policies to manage staff  
and transport to work on public holidays whenever possible 
Patient associated factors 
                      Cancer patients are generally immunpcompromised so there is  
high chance that they can develop chest infection,chicken pox,Herpes on the  
course of treatment.So necessary advice should be given to them to take  
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adequate nutrition and hygiene.When ever they develop any infection necessary  
care must be given for speedy recovery and restarting radiation as erly as  
possible 
Treatment associated factors 
                      Treatment breaks can occur due to acute radiation reactions and  
chemo related morbidity.Efforts must be taken to minimise radiation related  
morbility by adequately educating patient regarding personal hygiene,nutrition  
and care of radiated area.Any reactions that occur must be treated early.Chemo  
related morbidity must be kept in check by monitoring blood parameters and  
intervening at the earliest. 
Patient associated factors                         
                    For any treatment patient cooperation is very important.For  
radiotherapy patients cooperation is even more  important since they require to  
come every day.So patient must be taught the importance of everyday treatment  
and advice them to avoid absenting to treatment.Psychological and social   
support must be given to patient and family whenever possible. 
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                II.Objectives and methodology 
Aim of the study-  
                   To study the impact of treatment breaks during radiation therapy in 
 the survival of cervical cancer patients  also study other factors associated with  
survival of cervical cancer patient. 
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Specific objectives: 
          To assess the impact of treatment breaks during radiation therapy in the  
survival of cervical cancer patients 
          To study the pattern of treatment break  and association between overall  
treatment time and outcome in cervical cancer patients treated with external  
beam radiation with or without chemotherapy. 
          To study various factors that contribute to treatment breaks and  
management of treatment breaks  
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Study design- 
  It is a retrospective survival study 
          Patients treated as case of carcinoma cervix  International Federation of  
Gynaecology and Obstetrics Stage I-IV,who  were treated with external beam  
radiation to pelvis with or without chemotherapy  registered from 2010-2012  
were studied. 
        Patients’ age, weight, comorbidity, stage, treatment details and time trend  
are collected from the records 
 
Statistical analysis: 
          The data will be entered using Epi Data 3.0 and statistical analysis will be  
done using SPSS software.Survival analysis will be done by generating the  
Kaplan Meir survival curve.Cox propostional hazard model will be employed to  
estimate incidence of survival factors 
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Inclusion criteria: 
i)Histologically proven carcinoma of the uterine cervix,treated with curative  
intent with initial EBRT of 45-50Gy using conventional/conformal  
technique,with or without concurrent chemotherapy followed by HDR ICA 
ii)No evidence of metastasis, in Chest x - ray, USG abdomen normal, no  
palpable lymphadenopathy 
Exclusion criteria: 
i. Metastatic disease 
ii.Palliative intent 
iii.Recurrent disease 
iv.H/O Treatment for other malignancies 
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Institute Data: 
In a retrospective study where local tumour control in 102 patients with  
carcinoma cervix has been examined in relation to occurrence of gaps during  
radio therapy during the months of September to December 2015 in Cancer  
institute Adyar Chennai. This time period was chosen since there was historical  
floods in Chennai during the month of December 2015. This study includes  
stage II, III diseases with time gap exceeding 15 days taken as significant. All  
patients had change in brachytherapy schedule of 650cGy at point A twice a  
weeks in 2 weeks instead of weekly 800cGy per fraction thrice a week. Main  
outcomes measures were local recurrence in the irradiated volume.  
Results: 
Radiotherapy was completed without any unplanned interruption in 90/102  
patients. The 12 patients who had interruption were due to floods. 8 patients left  
to their home before intracavitary application and were not able to report on  
time,among them 4 had progressive diseas 4 patients had breaks during the  
course of external radiation,among them 1 had progressive disease 
This small analysis states that the gap during external radiation and the  
brachytherapy plays a vital role in causing local failure. Significant gaps in  
treatment should be  avoided.  
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RESULTS 
              
                                           AGE DISTRIBUTION 
 
 
 
      The most common age group world wide for cervical cancer is 55-59  
Years.It is less common in women lesser than 20 years or more than 80 
years.Younger the age at presentation worser the prognosis. 
     In our study also incidence is more in women 51-60 years with peak  
Incidence in women 41-50 years of age.Incidence in less than 30 years is  
only around 3% and incidence above 80 years is around 2%.Geriatic  
patients need special care . 
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                                                           COMORBIDS 
 
 
               Diabetis and hypertension are the most common comorbids in  
Indian population where as comorbids like hypothyroidism,bronchial  
asthma,auto immune diseases are less common.Uncontrolled comorbids  
like hypertension and diabetis can adversely affect outcome in patients with  
cancer since it makes then easily vulnerable to chemo related toxicity. 
              In our study population most common comorbid illness was  
diabetis which is around 25% followed by systemic hypertension which is  
around 20%.Aroung 60% of the study population did not have any  
significant comorbid illness        
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                                 HISTOLOGICAL DISTRIBUTION 
 
 
         The most common histology globally is squamous cell carcinoma 
which accounts for around 90% of total cases followed by  
adenocarcinoma which is around 7-10%.Followed by other minor  
histologies like clear cell carcinoma,neuroendocrine carcinoma ,small  
carcinoma ,adenosquamous carcinomawhich accounts for nearly 3% of  
the cervical carcinoma patients . 
          In our study the most common histology is squamous cell  
carcinoma which accounts for 88%of the population.Followed by  
adenocarcinoma which accounts for 6% the study population. 
Adenosquamous carcinoma accounts for 2% and other less common  
Types like neuroendocrine clear cell carcinoma accounts for 4% 
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                                          STAGE  DISTRIBUTION 
 
                    
 
             Early stage cervical cancer includes patients with  
stage I B –IIA2 and locally advanced cervical cancer is stage IIB- 
IVA. In general early stage cervical cancers are more common than  
Locally advanced.In our study also out of the total population of  
1054 early cervical cancer includes 557 and locally advanced 485,   
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                                      ICA DISTRIBUTION 
 
 
 
 
     In our study population  most patients around 96% received ICA and  
4% has not received ICA probable becaue of patient being medically  
unfit or Ica not feasible due to nature of the disease   
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                         CHEMORADIATION/RADIATION 
 
 
          Treatment of choice when ever patient is fit is concurrent  
chemoradiation.Total of 637 patients have received concurrent  
chemoradition out of 1054 and 405 patients have received only radical  
radiation  probable because of patient being unfit for chemotherapy or  
because of unwilling ness to chemotherapy 
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                           DISTRIBUTION ACCORDING TO TECHNIQUE 
                  
 
 
              
               Various RT techniques are used while treating patients with  
cervical cancer.In our study the most common technique used is  
3D conformal treatment planning around 62% and conventional 2D  
planning used in 34% patients ,IMRT used in 1% and VMAT in 3% of  
the total study population.  
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                DISTRIBUTION OF DISTANT METASTASIS  
 
 
The distribution of distant metastasis in our study population is  
almost similar to the seen in the general population.Of the 
patients who developed distant metastasis 50% developed in the lungs , 
25% developed in liver metastasis, 20% developed in paraaortic nodal  
metastasis and 18% developed in supraclavicular nodes . 
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                             TREATMENT INTERRUPTION 
 
 
 
 
 DEFINING OVERALL TREATMENT TIME: 
            An overall treatment time of 55+/- 3days is taken as treatment without  
interruption 
        
            Out of the total 1054 patients 950 completed treatment without   
significant interruptions  104 patients completed treatment with  
significant treatment interruption with an increase in overall treatment  
period.  
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                               TIMING OF INTERRUPTION 
 
 
         Of the 104 patients who had treatment interruption 83 had it during EBRT  
21 patients during ICA 
 
                                          CAUSE OF INTERRUPTION 
 
          Treatment associated interruption for 65 patients.Patient  associated   
interruption for 21 patients and intercurrent infection associated interruption   
for 18 patients 
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COMPARING PATIENTS WHO HAD TREATMENT INTERRUPTION WITH THOSE      
WHO HAD NO INTERRUPTION 
 
 INTERRUPTION  NO INTERRUPTION P VALUE  
LOCAL 
FAILURE  
28%  19%  0.01*  
DISTANT 
FAILURE  
14%  12%  0.8  
5 YR DFS  61%  70%  0.04*  
5 YR OS  60%  70%  0.03*  
 
              The local failure rate was 28% in the treatment interruption 
arm compared to 19% in the uninterrupted arm which is quiet significant  
The 5 year disease free survival and 5 year overall survival was also  
significantly better in patients who had their treatment completed without  
interruptions.However the distant failure rate is almost same. 
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SURVIVAL CURVE FOR TREATMENT INTERRUPTION WITH THOSE      
WHO HAD NO INTERRUPTION 
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COMPARING PATIENTS WHO HAD TREATMENT INTERRUPTION  DURING 
EXTERNAL BEAM RADIATION WITH THOSE    WHO HAD  INTERRUPTION 
DURING ICA 
 
 
 
 
ICA INTERRUPTION  EBRT 
INTERRUPTION  
P VALUE  
LOCAL 
FAILURE  
38%  28%  0.3  
DISTANT  9.5%  17% 0.4  
5 YEAR DFS  62%  67%  0.6  
5 YEAR OS  61%  66%  0.8  
 
               The local failure rate was 38% in patient who had interruption during  
External beam radiation and 28% in patients who had interruption during  
ICA.Though this is not statistically significant there is a slight difference  
favouring Increasing local failure in ICA arm on comparing with ICA  
arm.Whereas surprisinglydistant failure is more in EBRT arm.There was no big  
difference in 5 year overall survival and 5 year disease free survival in both  
arms. 
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SURVIVAL CURVE FOR TREATMENT INTERRUPTION  DURING 
EXTERNAL BEAM RADIATION WITH THOSE    WHO HAD  
INTERRUPTION DURING ICA 
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COMPARING PATIENTS WHO HAD TREATMENT INTERRUPTION  MORE THAN 
10 DAYS  WITH THOSE   WHO HAD  INTERRUPTION FOR LESS THAN 10 DAYS 
 
 EBRT INTERRUPTION 
> 10 DAYS  
EBRT 
INTERRUPTION <10 
DAYS  
P 
VALUE  
LOCAL 
FAILURE  
30%  23%  0.27  
DISTANT 
FAILURE  
15%  15%  0.09  
5 YEAR 
DFS  
55%  62%  0.07  
5 YEAR 
OS  
55%  62%  0.07  
 
                 The patients who had treatment interruption for greater than  
10 days had local failure of 30% compared to 23% local failure in  
patients who had interruption for less than 10 days,which is not a  
significant difference.Earlier studies done also shows similar results  
when 2 weeks interruptions where compared with less than 2 weeks  
interruption.  But there was no difference in distant failure ,5 year overall  
survival and disease free survival 
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COMPARING PATIENTS WITH EARLY CERVICAL CARCINOMA WITH 
INTERRUPTION  AND WITHOUT INTERRUPTION  
         
 EARLY STAGE WITH 
INTERRUPTION  
EARLY STAGE 
WITHOUT 
INTERRUPTION  
P 
VALUE  
LOCAL 
FAILURE  
24%  13%  0.02*  
DISTANT 
FAILURE  
8.6%  11%  0.47  
5 YR DFS  68%  76%  0.18  
5 YEAR OS  68%  76%  0.18  
 
                Patients who were treated for early stage cervical cancer when  
there was treatment interruption the local failure was 24% which was  
very high when compared to patients to patients without interruption  
early cervical carcinoma.This difference is very significant.There was no  
chance in distant failure rate However.5 year overall survival and  
disease free survival was slightly better in early stage no interruptions  
patients 
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SURVIVAL  CURVE  FOR EARLY CERVICAL CARCINOMA WITH               
INTERRUPTION  AND WITHOUT INTERRUPTION 
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COMPARING PATIENTS WITH LOCALLY ADVANCED CERVICAL CARCINOMA 
WITH INTERRUPTION  AND WITHOUT INTERRUPTION  
 
 LACC WITH 
INTERRUPTION  
LACC WITHOUT 
INTERRUPTION  
P VALUE  
LOCAL 
FAILURE  
33%  25%  0.27  
DISTANT 
FAILURE  
21%  12% 0.09  
5 YEAR DFS  50%  63%  0.07  
5 YEAR OS  50%  63%  0.07  
            Patients who were treated for locally advanced cervical cancer  
when there was treatment interruption the local failure was 33% when  
compared to 25% patients to patients without interruption in locally  
advanced cervical carcinoma.This difference is not very significant.The  
distance failure was 50% in interruption arm compared to 12% in no  
interruption arm chance in distant failure rate However there was no  
difference in 5 year overall survival and disease free survival   
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SURVIVAL CURVE LOCALLY ADVANCED CERVICAL 
CARCINOMA WITH INTERRUPTION  AND WITHOUT 
INTERRUPTION 
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COMPARING PATIENTS WHO RECEIVED CONCURRENT CHEMORADIATION 
WITH INTERRUPTION  AND WITHOUT INTERRUPTION 
 
 
 CHEMO WTH 
INTERRUPTION  
CHEMO 
WITHOUT 
INTERRUPTION  
P VALUE  
LOCAL 
FAILURE  
30%  15%  0.002*  
DISTANT 
FAILURE  
10%  9%  0.7  
5 YEAR DFS  63%  74%  0.04*  
5 YEAR OS  64%  74%  0.07  
      
 
       Patients who received chemoradiation when treatment interrupted  
has local failure  of 30% compared to chemo radiation patients who  
had 15% local failure in treatment interruption arm this does not imply  
that patient despite receiving chemoradiation have failed locally,it means  
that in spite of receiving chemotherapy when there is a treatment break  
patient can still fail locally.There was no difference in distant failure 5  
year overall survival and disease free survival 
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COMPARING PATIENTS WHO RECEIVED RADICAL RADIATION WITH 
INTERRUPTION  AND WITHOUT INTERRUPTION 
 
 NO CHEMO WITH 
INTERRUPTION  
NO CHEMO 
WITHOUT 
INTERRUPTION  
P 
VALUE  
LOCAL 
FAILURE  
23%  29%  0.4  
DISTANT 
FAILURE  
20%  18%  0.8  
5 YEAR DFS  57%  70%  0.12  
5 YEAR OS  57%  70%  0.12  
 
               Patients who received only radical radiation had no significant  
change in local failure.distant failure .But there was patients who had  
treatment without interruption had better 5 year overall survival and  
disease free survival 
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MANAGEMENT OF INTERRUPTION 
 
METHODS BENIFITS  POTENTIAL 
DIFFICULTY  
1)Overall time and dose per 
fraction is maintained by 
treating on weekend days as  
necessary.  
Overall time, fraction size, 
interfraction interval and 
therapeutic index 
maintained  
May not be feasible 
for interrupions 
occurring near the 
end of a schedule.  
2)Overall time and dose per 
fraction is maintained by 
treating twice daily as 
necessary.  
Overall time and fraction 
size maintained.  
Possible increase in 
late-normal tissue 
damage  
3) Overall time is maintained by 
increasing dose per fraction for 
same number of post-
interruption days as there were 
interrupions days  
Overall time maintained by 
accepting reduced number 
of fractions. Still utilises one 
fraction on each treatment 
day.  
Therapeutic index 
adversely affected  
4)Accept that treatment 
extension is unavoidable and 
deliver extra fractions, using 
increased dose per fraction to 
minimise the extension 
duration.  
Allows at least partial 
restoration of the prescribed 
schedule  
Therapeutic index 
adversely affected. 
Might require 
acceptance of both 
reduced tumour 
control and 
increased late effects  
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How to manage interruptions during combined EBRT and 
Brachytherapy 
 The corrections for treatment interruption in case of EBRT and BT are 
similar to those described for EBRT alone. 
 However in case of an inevitable interruption during external beam 
radiation,brachytherapy can be started early if patient disease is suitable 
 In breaks happening during High dose rate brachytherapy the fractions 
that are remaining and  intervals between each fractions in the remaining 
treatment time should be adjusted properly 
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CONCLUSION- 
This analysis states  
 Interruption during radiotherapy overall affect  local tumour 
control and survival in all stages of cervical carcinoma 
 Interrruption during radiotherapy  for early stage cervical cancer 
can also affect local control 
 Despite combining  chemotherapy with radiation treatment 
interruptions during radiation can significantly affect local control. 
 Though there is a difference in local control between patients who 
had interruptions for  less than or more than 10 days but still it has 
no major significance on survival and local control  
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Review of literature: 
1)Carcinoma uterine cervix –Impact of prolongation of overall treatment time and 
timing of brachytherapy outcome of radiation therapy  by Carlos.A.Perez  et al ,they 
analysed records of  1224 patients (Stage IB to III)  with definitive irradiation 
(combination of external beam and two intracavitary insertions to deliver doses of 70 
to 90 Gy to point A) were reviewed. Follow-up was obtained in 97% of the patients 
(median, 12 years; minimum, 3 years; maximum, 28 years).And found that 
prolongation of treatment time in patients with Stage IB, IIA, IIB, and III carcinoma of 
the uterine cervix has a significant impact on pelvic tumor control and CSS. The 
effect of OTT was present regardless of tumor size except in Stage IB tumors ≤3 cm. 
This may be related to biologic factors such as cell repopulation and increased 
proliferation resulting from treatment interruptions, in addition to initial clonogenic 
cells burden. Irradiation for patients with invasive carcinoma of the cervix should be 
delivered in the shortest possible overall time 
2) Effect of total treatment time on event free survival in carcinoma of cervix by 
Delaloye et al analysed 360 with stage IB-IIIB carcinoma of the cervix were treated 
with external radiation and brachytherapy as first line therapy. Therapy duration was 
45 days. Patients were classified according to whether they had rather long 
therapies, taking 60 cutoff. Cumulative incidences of local recurrence, metastasis, 
and death were estimated. The 5-year event-free survival rate was better in patients 
who had treatment time of less than 60 days .In terms of univariate hazard ratio 
(HR), the relative difference between the two groups corresponds to an increase in 
hazard of any of the three events considered more than the double (HR = 1.756, P = 
0.003) for the longer therapy duration group. A multivariate analysis, which included 
selected prognostic factors, confirmed these results (HR = 1.76, P = 0.017). A short 
radiation therapy duration is a highly significant prognostic factor associated with 
longer event-free survival in carcinoma of the cervix. 
3) The adverse effect of treatment prolongation in cervical carcinoma by Shang  wen 
chen et al analysed 257 treated cases of carcinoma uterine cervix  (IB,IIA,II 
B,IIIA,IIIB,IV A ) patients , who underwent external radiotherapy with HDR  ICA and a 
minimum of 3 years of follow-up Median treatment time was 63 days found that For 
all stages of disease, the 5-year CSS and PCR were significantly different  
comparing treatment   times of less than and greater than or equal to 63 days [83% 
and 65% (P=0.004], 93% and 83% (P=0.02), respectively]. Multivariate analysis 
identified three  prognostic factors for CSS, stage (P<0.001), tumor response to 
external RT (P=0.001), and overall treatment time (OTT; P=0.006). 
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Prognostic factors for pelvic failure were stage (P<0.001), tumor response to external 
RT (P=0.001), and OTT (P=0.03).  
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